SPARC licenses commercialization rights of Elepsia XR to Tripoint Therapeutics

Sun Pharma Advanced Research Company has granted an exclusive license to Tripoint Therapeutics to commercialize Elepsia XR 1000 mg and Elepsia XR 1500 mg tablets in the United States.

Under terms of the license agreement, SPARC will be eligible to receive tiered royalties ranging from 15% to 50% on net sales. Tripoint will be responsible for all U.S. regulatory submissions and payment of annual PDUFA fees for Elepsia XR 1000 mg and Elepsia XR 1500 mg.

The initial term of the agreement is five years and may be further extended as per mutual agreement between the parties.

“Elepsia  can bring down the daily pill burden significantly and will be an alternative treatment option for patients suffering with epilepsy,” said Anil Raghavan, SPARC CEO.

“We are very excited about the relationship with SPARC and look forward to bringing Elepsia XR to patients in the United States,” Tripoint president Steve Squashic said.

Elepsia XR is an extended release formulation of levetiracetam 1000 mg/1500 mg, indicated as adjunctive therapy for the treatment of partial onset seizures in patients 12 years of age and older, developed using SPARC’s WrapMatrix technology.